Prospecção Científica e Tecnológica acerca da Covid-19: análise das abordagens terapêuticas farmacológicas inseridas no contexto pandêmico

Autores

  • Antonio Carlos Pereira de Oliveira Universidade Federal do Delta do Parnaíba- UFDPar
  • Darllan Damasceno Fontenele Universidade Federal do Delta do Parnaíba- UFDPar
  • Gabrielle Costa Sousa Universidade Federal do Delta do Parnaíba- UFDPar
  • Samara Sousa de Pinho Universidade Federal do Delta do Parnaíba- UFDPar
  • Katriane Carvalho da Silva Universidade Federal do Delta do Parnaíba- UFDPar
  • Ana Patrícia de Oliveira Universidade Federal do Piauí- UFPI
  • Lucas Antonio Duarte Nicolau Universidade Federal do Delta do Parnaíba- UFDPar
  • Jand Venes Rolim Medeiros Universidade Federal do Delta do Parnaíba- UFDPar

DOI:

https://doi.org/10.9771/cp.v13i2%20COVID-19.36194

Palavras-chave:

Hidroxicloroquina, Coronavírus, Tratamento

Resumo

O SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) é um vírus com alta capacidade de disseminação que pode causar uma forte pneumonia. Como ainda não há um tratamento efetivo recomendado pela Organização Mundial de Saúde (OMS), o presente estudo realizou uma prospecção científica e tecnológica, destacando possíveis tratamentos que possam ser eficazes no combate à Covid-19. A coleta de artigos e de patentes sobre o SARS-CoV-2 foi realizada por meio de palavras-chave nos bancos Web of Science, SciELO (Scientific Electronic Library Online), PubMed (Public MEDLINE) e Scopus e nas bases de patentes World Intellectual Property Organization (WIPO), United States Patent and Trademark Office (USPTO), Instituto Nacional de Propriedade Industrial (INPI) e European Patent Office (EPO). Na prospecção, foram contabilizados 81 artigos acerca do tratamento e nenhuma patente depositada nos bancos supracitados, evidenciando forte procura para o tratamento, apesar de não apresentar registro de patentes para o produto ou para o processo.

Downloads

Não há dados estatísticos.

Biografia do Autor

Antonio Carlos Pereira de Oliveira, Universidade Federal do Delta do Parnaíba- UFDPar

Laboratório da Farmacologia da Inflamação e Desordens Gastrintestinais- LAFIDG- Universidade Federal do Delta do Parnaíba- UFDPar

Darllan Damasceno Fontenele, Universidade Federal do Delta do Parnaíba- UFDPar

Laboratório da Farmacologia da Inflamação e Desordens Gastrintestinais- LAFIDG- Universidade Federal do Delta do Parnaíba- UFDPar

Gabrielle Costa Sousa, Universidade Federal do Delta do Parnaíba- UFDPar

Laboratório da Farmacologia da Inflamação e Desordens Gastrintestinais- LAFIDG- Universidade Federal do Delta do Parnaíba- UFDPar

Samara Sousa de Pinho, Universidade Federal do Delta do Parnaíba- UFDPar

Laboratório da Farmacologia da Inflamação e Desordens Gastrintestinais- LAFIDG- Universidade Federal do Delta do Parnaíba- UFDPar

Katriane Carvalho da Silva, Universidade Federal do Delta do Parnaíba- UFDPar

Laboratório da Farmacologia da Inflamação e Desordens Gastrintestinais- LAFIDG- Universidade Federal do Delta do Parnaíba- UFDPar

Ana Patrícia de Oliveira, Universidade Federal do Piauí- UFPI

Programa de Pós-graduação em Biotecnologia-RENORBIO-Universidade Federal do Piauí

Laboratório da Farmacologia da Inflamação e Desordens Gastrintestinais- LAFIDG- Universidade Federal do Delta do Parnaíba- UFDPar

Lucas Antonio Duarte Nicolau, Universidade Federal do Delta do Parnaíba- UFDPar

Laboratório da Farmacologia da Inflamação e Desordens Gastrintestinais- LAFIDG- Universidade Federal do Delta do Parnaíba- UFDPar

Jand Venes Rolim Medeiros, Universidade Federal do Delta do Parnaíba- UFDPar

Programa de Pós-graduação em Biotecnologia- Universidade Federal do Delta do Parnaíba- UFDPar

Laboratório da Farmacologia da Inflamação e Desordens Gastrintestinais- LAFIDG- UFDPar

Referências

ASHOUR, H. M. et al. Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens, v. 9, n. 3, p. 1–15, 2020. DOI: 10.3390/pathogens9030186.

BARON, S. A. et al. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? International Journal of Antimicrobial Agents, [S.l.], p. 1-6, 2020. DOI:10.1016/j.ijantimicag.2020.105944.

CAO, B. et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine, [S.l.], p. 1-13, 2020a. DOI: 10.1056/NEJMoa2001282.

CAO, J. et al. Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, China. Clinical Infectious Diseases, [S.l.], 2020b. DOI:10.1093/cid/ciaa243.

CHEN, E. Q. et al. Brief report of the first cured 2019-nCoV pneumonia patient in West China Hospital. European Journal of Clinical Microbiology & Infectious Diseases, [S.l.], p. 1-3, 2020a. DOI: 10.1007/s10096-020-03866-z.

CHEN, Q. et al. A report of clinical diagnosis and treatment of 9 cases of coronavirus disease 2019. Journal of medical virology, [S.l.], p.1-5, 2020b. DOI:10.1002/jmv.25755.

CHEN, Y. W.; YIU, C. B.; WONG, K. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000 Research, [S.l.], v. 9, 2020. DOI:10.12688/f1000research.22457.1

CUI, Y. et al. A 55-Day-Old Female Infant infected with COVID 19: presenting with pneumonia, liver injury, and heart damage. The Journal of Infectious Diseases, [S.l.], p. 1-7, 2020. DOI:10.1093/infdis/jiaa113.

DENG, S. Q.; PENG, H. J. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. Journal of Clinical Medicine, [S.l.], v. 9, n. 2, p. 575, 2020.

DROSTEN, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. New England journal of medicine, [S.l.], v. 348, n. 20, p. 1.967-1.976, 2003.

ELFIKY, A. A. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sciences, [S.l.], p. 117477, 2020a. DOI:10.1016/j.lfs.2020.117477.

ELFIKY, A. A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sciences, [S.l.], p. 117.592, 2020b. DOI: 10.1016/j.lfs.2020.117592.

FAN, H. et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model. Chinese Medical Journal, [S.l.], 2020. DOI: 10.1097/CM9.0000000000000797.

FU, Y.; CHENG, Y.; WU, Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virologica Sinica, [S.l.], v. 12.250, 2020. DOI: 10.1007/s12250-020-00207-4.

GAUTRET, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, [S.l.], p. 1-25, 2020. DOI:10.1016/j.ijantimicag.2020.105949.

GAO, J.; TIAN, Z.; YANG, X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends, [S.l.], 2020. DOI:10.5582/bst.2020.01047.

GRALINSKI, L. E.; MENACHERY, V. D. Return of the Coronavirus: 2019-nCoV. Viruses, [S.l.], v. 12, n. 2, p. 135, 2020.

HOFFMANN, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, [S.l.], p. 1-10, 2020. DOI: 10.1016/j.cell.2020.02.052.

HUANG, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, [S.l.], v. 395, n. 10.223, p. 497-506, 2020.

INCIARDI, R. M. et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology, [S.l.], 2020. DOI: 10.1001/jamacardio.2020.1096

KHALILI, J. S. et al. Novel coronavirus treatment with ribavirin: Groundwork for evaluation concerning COVID-19. Journal of Medical Virology, [S.l.], 2020. DOI:10.1002/jmv.25798.

KHAN, S. A. et al. Identification of Chymotrypsin-like Protease Inhibitors of SARS-CoV-2 Via Integrated Computational Approach. Journal of Biomolecular Structure and Dynamics, [S.l.], 2020. DOI: 10.1080/07391102.2020.1751298

LAI, C. C. et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. International Journal of Antimicrobial Agents, [S.l.], v. 55, n. 3, p. 105924, 2020.

LAUER, S. A. et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of Internal Medicine, [S.l.], 2020. DOI: 10.7326/M20-0504.

LIAN, J. et al. Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan. Clinical Infectious Diseases, [S.l.], 2020. DOI:10.1093/cid/ciaa242.

LIM, J. et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. Journal of Korean Medical Science, [S.l.], v. 35, n. 6, p. 1-6, 2020.

LING, Y. et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chinese Medical Journal, [S.l.], 2020. DOI: 10.1097/CM9.0000000000000774.

LIU, F. et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. International Journal of Infectious Diseases, [S.l.], 2020a. DOI: 10.1016/j.ijid.2020.03.013.

LIU, J. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery, [S.l.], v. 6, n. 1, p. 1-4, 2020b.

LIU, Y. et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences, [S.l.], v. 63, n. 3, p. 364-374, 2020c.

LIU, W. et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chinese medical journal, [S.l.], 2020d. DOI: 10.1097/CM9.0000000000000775.

LIU, S.; ZHENG, Q.; WANG, Z. Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus. Bioinformatics, [S.l.], 2020. DOI: 10.1093/bioinformatics/btaa224.

LUNG, J. et al. The potential chemical structure of anti‐SARS‐CoV‐2 RNA‐dependent RNA polymerase. Journal of Medical Virology, [S.l.], 2020. DOI:10.1002/jmv.25761.

NI, L. et al. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan. Frontiers of Medicine, [S.l.], p. 1-5, 2020. DOI: 10.1007/s11684-020-0757-x.

ORTEGA, J. et al. Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target. EXCLI Journal, [S.l.], v. 19, p. 400, 2020. DOI: 10.17179/excli2020-1189.

QUINTELLA, C. M.; MATA, A. M. T.; GHESTI, G. F. Vacinas para Coronavírus (COVID-19; SARS- COV-2): mapeamento preliminar de artigos, patentes, testes clínicos e mercado. Cadernos de Prospecção, Salvador, v. 13, n. 1, p. 3-12, março, 2020. DOI: 10.9771/cp.v13i1.35871.

ROBSON, B. Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus. Computers in Biology and Medicine, [S.l.], p. 103670, 2020. DOI: 10.1016/j.compbiomed.2020.103670.

RUNFENG, L. Lianhuaqingwen exerts anti-viral and anti-inflammatory activityagainst novel coronavirus (SARS-CoV-2). Pharmacological Research, [S.l.], v. 104.761, 2020. DOI: 10.1016/j.phrs.2020.104761.

SHANMUGARAJ, B. et al. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pacific Journal of Allergy and Immunology, [S.l.], v. 38, n. 1, p. 10-18, 2020. DOI: 10.12932/AP-200220-0773.

SUN, D. et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World Journal of Pediatrics, [S.l.], 2020. DOI: 10.1007/s12519-020-00354-4.

TAI, W. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cellular & Molecular Immunology, [S.l.], p. 1-8, 2020. DOI: 10.1038/s41423-020-0400-4.

WAN, S. et al. Clinical Features and Treatment of COVID‐19 Patients in Northeast Chongqing. Journal of Medical Virology, [S.l.], p. 1-10, 2020. DOI:10.1002/jmv.25783.

WANG, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama, [S.l.], 2020a. DOI: 10.1001/jama.2020.1585.

WANG, Z. et al. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clinical Infectious Diseases, [S.l.], p. 1-27, 2020b. DOI: 10.1093/cid/ciaa272.

WANG, Z. et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Bioscience Trends, [S.l.], p. 1-5, 2020c. DOI: 10.5582/bst.2020.01030.

WHO – WORLD HEALTH ORGANIZATION. Coronavirus disease (COVID-19) Situation dashboard. 2020. Disponível em: https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd. Acesso em: 2 abr. 2020.

WIT, E. et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Sciences, [S.l.], v. 117, n. 12, p. 6.771-6.776, 2020.

WU, C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Internal Medicine, [S.l.], 2020. DOI:10.1001/jamainternmed.2020.0994.

WU, D.; YANG, X. O. Th17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor fedratinib. Journal of Microbiology, Immunology and Infection, [S.l.], 2020. DOI:10.1016/j.jmii.2020.03.005.

XU, K. et al. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. Zhejiang da xue xue bao. Yi xue ban= Journal of Zhejiang University. Medical sciences, [S.l.], v. 49, n. 1, p. 0-0, 2020. DOI: 10.3785/j.issn.1008-9292.2020.02.02.

YAO, X. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases, [S.l.], p. 1-25, 2020. DOI:10.1093/cid/ciaa237.

YETHINDRA, V. Role of GS-5734 (Remdesivir) in inhibiting SARS-CoV and MERS-CoV: The expected role of GS-5734 (Remdesivir) in COVID-19 (2019-nCoV)-VYTR hypothesis. International Journal of Research in Pharmaceutical Sciences, [S.l.], v.11 (SPL1), p. 1-6, 2020. DOI:10.26452/ijrps.v11iSPL1.1973.

YANG, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine, [S.l.], 2020. DOI:10.1016/S2213-2600(20)30079-5.

YOUNG, B. E. et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. Jama, [S.l.], 2020. DOI: 10.1001/jama.2020.3204.

YUAN, J. et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflammation Research, [S.l.], p. 1-8, 2020. DOI:10.1007/s00011-020-01342-0.

ZHANG, D. et al. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. Journal of Integrative Medicine, [S.l.], v. 18, n. 2, p. 152-158, 2020.

ZHONG, N. S. et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. The Lancet, [S.l.], v. 362, n. 9393, p. 1.353-1.358, 2003.

ZHOU, D.; DAI, S. M.; TONG, Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. Journal of Antimicrobial Chemotherapy, [S.l.], p. 1-4, 2020a. DOI:10.1093/jac/dkaa114.

ZHOU, Y. et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discovery, [S.l.], v. 6, n. 1, p. 1-18, 2020b. DOI: 10.1038/s41421-020-0153-3.

ZHU, L. et al. Successful recovery of COVID‐19 pneumonia in a renal transplant recipient with long‐term immunosuppression. American Journal of Transplantation, [S.l.], p. 1-6, 2020. DOI:10.1111/ajt.15869.

Downloads

Publicado

2020-04-16

Como Citar

Pereira de Oliveira, A. C., Damasceno Fontenele, D., Costa Sousa, G., Sousa de Pinho, S., Carvalho da Silva, K., de Oliveira, A. P., Duarte Nicolau, L. A., & Rolim Medeiros, J. V. (2020). Prospecção Científica e Tecnológica acerca da Covid-19: análise das abordagens terapêuticas farmacológicas inseridas no contexto pandêmico. Cadernos De Prospecção, 13(2 COVID-19), 559. https://doi.org/10.9771/cp.v13i2 COVID-19.36194

Edição

Seção

Coronavirus (SARS-COV-2) e COVID-19